Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Rechercher Study Connect
  • NCT06764485

Recruiting

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer - CA071-1000

Mis à jour: 9 avril, 2025   |   ClinicalTrials.gov

Celgene Corporation, filiale entièrement détenue par Bristol-Myers Squibb Company 

Résumé imprimable

VOUS ENVISAGEZ CET ESSAI ?
Imprimer cette page et le guide d’essai pour vous aider à parler avec votre médecin.
Utiliser le Guide du participant à l’étude pour découvrir comment participer à un essai clinique. Comprendre les principaux facteurs à envisager avant de prendre une décision et poser des questions à votre équipe soignante.
Imprimer cette page CA071-1000
Télécharger le guide du participant à l’étude

SÉLECTIONNER LA LANGUE

Détails de l’essai

  • Phase 3

    Phase

  • Sexe(s)

  • 18+

    Tranche d’âge

  • 162

    Site(s)

  • Recruiting

Options de traitement

Bras de l’étude
INTERVENTION ASSIGNÉE
Active Comparator: Part 1: Comparator 1
Drug: Enzalutamide, Abiraterone, Predinsone/Prednisolone
Active Comparator: Part 1: Comparator 2
Drug: Docetaxel, Predinsone/Prednisolone
Experimental: Part 1: Dose 1
Drug: BMS-986365
Experimental: Part 1: Dose 2
Drug: BMS-986365
Active Comparator: Part 2: Comparator 1
Drug: Enzalutamide, Abiraterone, Predinsone/Prednisolone
Active Comparator: Part 2: Comparator 2
Drug: Docetaxel, Predinsone/Prednisolone
Experimental: Part 2: Dose Selected
Drug: BMS-986365

Principaux critères d’éligibilité

Inclusion Criteria - Participants must have histologic or cytologic confirmation of adenocarcinoma of the prostate without small cell or neuro-endocrine features. - Participants must have current evidence of metastatic disease documented by either bone lesions on radionuclide bone scan and/or soft tissue lesions on computed tomography/magnetic resonance imaging (CT/MRI). - Participants must be asymptomatic or mildly symptomatic from prostate cancer with score on Brief Pain Inventory - Short Form (BPI-SF) that must be < 4. - Participants must have had previous treatment with an androgen receptor pathway inhibitor (abiraterone, enzalutamide, apalutamide, or darolutamide). Exclusion Criteria - Participants must not have impaired cardiac function or clinically significant cardiac disease. - Participants must not have any brain metastasis. - Participants must not have any liver metastasis. - Participants with superscan on technetium-99m (Tc-99m) radionuclide bone scans. - Other protocol-defined Inclusion/Exclusion criteria apply.

Nous vous recommandons vivement de contacter BMS pour signaler les effets secondaires (événements indésirables)
Les effets secondaires (événements indésirables) et les autres événements à signaler sont définis ici
Signaler des plaintes concernant des effets indésirables (effets indésirables) ou des produits: Informations médicales